AI Engines For more Details: Perplexity Kagi Labs You
Urinary Tract Infections (UTIs): Cinoxacin is effective against a wide range of bacteria commonly implicated in urinary tract infections, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter species. It is often prescribed for uncomplicated UTIs, such as cystitis and pyelonephritis, where it can help alleviate symptoms and eradicate the infection.
Prostatitis: Cinoxacin may also be used in the treatment of bacterial prostatitis, an inflammation of the prostate gland usually caused by bacterial infection. It can penetrate prostatic tissues and achieve therapeutic concentrations in the prostate, making it effective against causative pathogens.
Gastrointestinal Infections: In some cases, cinoxacin may be prescribed for gastrointestinal infections caused by susceptible bacteria. This includes infectious diarrhea caused by certain strains of bacteria such as Shigella and Salmonella.
Respiratory Tract Infections: Cinoxacin is not typically used as a first-line treatment for respiratory tract infections. However, in some cases where the causative bacteria are known to be susceptible to cinoxacin, it may be considered for the treatment of respiratory infections such as bronchitis or pneumonia.
Skin and Soft Tissue Infections: Cinoxacin is not commonly used to treat skin and soft tissue infections. Other antibiotics are usually preferred for these types of infections, as they may be more effective and have a lower risk of developing bacterial resistance.
Side Effects: Like all antibiotics, cinoxacin can cause side effects. Common side effects may include nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, and skin rash. Rare but serious side effects may include tendon rupture, particularly in older adults, and central nervous system effects such as seizures or hallucinations.
Drug Interactions: Cinoxacin may interact with certain medications, potentially affecting their effectiveness or increasing the risk of side effects. It is important to inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting cinoxacin therapy.
Pregnancy and Lactation: The safety of cinoxacin use during pregnancy and lactation has not been well established. It is generally not recommended for use in pregnant or breastfeeding women unless the potential benefits outweigh the risks.
Bacterial Resistance: Like other antibiotics, the overuse or misuse of cinoxacin can contribute to the development of bacterial resistance, reducing its effectiveness in treating infections. It is important to use cinoxacin judiciously and only when necessary to help preserve its efficacy.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 3.1 | 0.9 | 2.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.2 | 1.5 | 1.13 |
| Allergies | 5.4 | 2 | 1.7 |
| Allergy to milk products | 1.4 | 1.6 | -0.14 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 5.9 | 4.9 | 0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1.2 | 1.75 |
| Ankylosing spondylitis | 3.1 | 0.7 | 3.43 |
| Anorexia Nervosa | 1.3 | 2.3 | -0.77 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 4.5 | 1.8 | 1.5 |
| Atherosclerosis | 2.1 | 2.2 | -0.05 |
| Atrial fibrillation | 3.5 | 2.3 | 0.52 |
| Autism | 7.4 | 6.9 | 0.07 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 1.8 | 1.8 | |
| Cancer (General) | 0.6 | 1.1 | -0.83 |
| Carcinoma | 4.4 | 1.7 | 1.59 |
| Celiac Disease | 3.1 | 2.4 | 0.29 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 3.6 | 4.1 | -0.14 |
| Chronic Kidney Disease | 3.2 | 1.5 | 1.13 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.7 | 0.18 |
| Chronic Urticaria (Hives) | 2 | 0.7 | 1.86 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 2.8 | 1.3 | 1.15 |
| Colorectal Cancer | 8.1 | 2.5 | 2.24 |
| Constipation | 2.1 | 1 | 1.1 |
| Coronary artery disease | 1.9 | 2.5 | -0.32 |
| COVID-19 | 6.2 | 5.8 | 0.07 |
| Crohn's Disease | 7.9 | 3.9 | 1.03 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.3 | -0.08 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.4 | 1.1 | 2.09 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 8.2 | 6.7 | 0.22 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.9 | -0.06 |
| Endometriosis | 3.5 | 1.7 | 1.06 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.7 | 1.8 | 1.06 |
| erectile dysfunction | 1.6 | 0.3 | 4.33 |
| Fibromyalgia | 3.2 | 2.6 | 0.23 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 2.8 | 0.71 |
| gallstone disease (gsd) | 3.5 | 1.1 | 2.18 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 0.4 | 5 |
| Generalized anxiety disorder | 2.9 | 2 | 0.45 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.8 | 0.5 |
| Graves' disease | 1.3 | 2.7 | -1.08 |
| Gulf War Syndrome | 0.9 | 1.1 | -0.22 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 3 | 0.9 | 2.33 |
| Heart Failure | 4.2 | 2 | 1.1 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.9 | 0.3 | 5.33 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0 | 0 |
| hyperglycemia | 1.9 | 1.2 | 0.58 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.3 | 3 | 0.1 |
| Hypothyroidism | 0.9 | 1 | -0.11 |
| Hypoxia | 3.6 | 0.3 | 11 |
| IgA nephropathy (IgAN) | 1.6 | 2.2 | -0.38 |
| Inflammatory Bowel Disease | 7.3 | 5.4 | 0.35 |
| Insomnia | 1.9 | 1.9 | 0 |
| Intelligence | 2.2 | 0 | 0 |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 5.5 | 3.8 | 0.45 |
| ischemic stroke | 2.4 | 1.7 | 0.41 |
| Liver Cirrhosis | 6.4 | 4.6 | 0.39 |
| Long COVID | 4.4 | 3.7 | 0.19 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 0.8 | 0.13 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 0.5 | 1 | -1 |
| ME/CFS without IBS | 1.2 | 1.3 | -0.08 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.6 | -0.5 |
| Metabolic Syndrome | 6 | 6.2 | -0.03 |
| Mood Disorders | 7 | 5.3 | 0.32 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 5.9 | 4.2 | 0.4 |
| Multiple system atrophy (MSA) | 0.3 | 0.4 | -0.33 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.7 | -4.67 |
| Neuropathy (all types) | 0.7 | 1.9 | -1.71 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 2.1 | 0.71 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 6.2 | 6.2 | 0 |
| obsessive-compulsive disorder | 4.8 | 2.4 | 1 |
| Osteoarthritis | 2.3 | 0.9 | 1.56 |
| Osteoporosis | 2.2 | 1.6 | 0.38 |
| pancreatic cancer | 2.1 | 0.6 | 2.5 |
| Parkinson's Disease | 6.1 | 5.8 | 0.05 |
| Polycystic ovary syndrome | 5.3 | 2.1 | 1.52 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 1.2 | 1.3 | -0.08 |
| Primary sclerosing cholangitis | 2.1 | 1.2 | 0.75 |
| Psoriasis | 2.5 | 2 | 0.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.1 | 3.9 | 0.31 |
| Rosacea | 0.3 | 1 | -2.33 |
| Schizophrenia | 5 | 2.5 | 1 |
| scoliosis | 0.9 | 0.3 | 2 |
| Sjögren syndrome | 1.8 | 2.6 | -0.44 |
| Sleep Apnea | 1.6 | 1.5 | 0.07 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.1 | 21 |
| Stress / posttraumatic stress disorder | 3.2 | 2.2 | 0.45 |
| Systemic Lupus Erythematosus | 4.1 | 1 | 3.1 |
| Tic Disorder | 0.9 | 0.9 | 0 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.2 | 2.7 | 0.56 |
| Type 2 Diabetes | 6.8 | 6.5 | 0.05 |
| Ulcerative colitis | 6.3 | 5.5 | 0.15 |
| Unhealthy Ageing | 5.1 | 1.9 | 1.68 |
| Vitiligo | 1.9 | 1.2 | 0.58 |
